Stock RHO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Roche Holding AG Share Price BOERSE MUENCHEN

Equities

RHO

CH0012032113

Pharmaceuticals

Real-time BOERSE MUENCHEN
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Roche Holding AG -.--% -.--%
06-15 Roche?s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma CI
06-14 Roche: collaboration agreement in colon cancer CF
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 60.61B 68.05B 63.56B 5,370B Sales 2025 * 63.99B 71.84B 67.11B 5,669B Capitalization 200B 225B 210B 17,735B
Net income 2024 * 13.25B 14.88B 13.9B 1,174B Net income 2025 * 14.74B 16.55B 15.46B 1,306B EV / Sales 2024 * 3.54 x
Net Debt 2024 * 14.08B 15.81B 14.77B 1,248B Net Debt 2025 * 9B 10.1B 9.44B 797B EV / Sales 2025 * 3.27 x
P/E ratio 2024 *
14.6 x
P/E ratio 2025 *
13.2 x
Employees -
Yield 2024 *
3.95%
Yield 2025 *
4.06%
Free-Float 88.91%
More Fundamentals * Assessed data

Chart Roche Holding AG

Dynamic Chart

Latest news about Roche Holding AG

Roche?s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma CI
Roche: collaboration agreement in colon cancer CF
Nkarta, Inc. Appoints George Vratsanos as Board of Directors CI
AbbVie inks immune disorder drug licensing deal with China's FutureGen RE
Swiss Stocks Flash Red as US Fed Decision Takes Spotlight MT
Global markets live: ABB, Roche, Microsoft, Apple, Tesla... Our Logo
Roche's Lung Cancer Drug Notches EU Win After 'Unprecedented' Late-stage Study Results MT
Roche: FDA clearance for virus test CF
Roche: EU approval for lung cancer CF
Roche Secures EU Approval for Early-Stage Lung Cancer Treatment MT
Roche Obtains US FDA Emergency Use Permit for Four-in-one Molecular Test MT
Roche: efficacy of Evrysdi in spinal muscular atrophy CF
Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT
AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Buy Recommendation MT
More news

Latest transcript on Roche Holding AG

Logo Roche Holding AG
Roche Holding AG - Shareholder/Analyst Call
More transcripts

Analyst Recommendations on Roche Holding AG

AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Buy Recommendation MT
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating ZD
ROCHE HOLDINGS AG : Goldman Sachs reaffirms its Sell rating ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS ZD
ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating ZD
More recommendations

Press releases Roche Holding AG

Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation BU
Roche and Hitachi High-Tech extend their long-standing partnership AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation BU
More press releases

News in other languages on Roche Holding AG

Aktien Schweiz schlagen sich erneut wacker
Roche : accord de collaboration dans le cancer du côlon
Les gagnants raflent tout
AVIS D'ANALYSTES DU JOUR : Air Liquide, Stellantis, Lonza, Ageas, Solvay, Roche, Nacon...
OPINIONI DEGLI ANALISTI : TIM, Unipol Gruppo, Ulisse Biomed, Webuild, OVS, Telefónica, Air Liquide, Stellantis, Lonza, Ageas, Solvay, Roche...
More news

Managers and Directors - Roche Holding AG

Managers TitleAgeSince
Thomas Schinecker CEO
 Chief Executive Officer 49 31/12/02
Severin Schwan CHM
 Chairman 57 31/12/07
Alan Hippe DFI
 Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Bernard Poussot BRD
 Director/Board Member 72 02/03/15
Ulf Mark Schneider BRD
 Director/Board Member 59 -
André S. Hoffmann BRD
 Director/Board Member 66 31/12/95
More insiders

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
12:00pm - European Hematology Association Congress
Related indices
SMI , STOXX EUROPE 600 (EUR)
More about the company

Income Statement Evolution

More financial data

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
NOVARTIS AG Stock Novartis AG
+11.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RHO Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW